Sansure Biotech Inc. (SHA:688289)

China · Delayed Price · Currency is CNY

16.72

+0.45 (2.77%)

Sep 30, 2026, 3:00 PM CST

Market Cap	9.50B -19.4%
Revenue (ttm)	1.61B -0.2%
Net Income	134.24M -52.3%
EPS	0.23 -52.0%
Shares Out	568.11M
PE Ratio	72.60
Forward PE	38.29
Dividend	0.52 (3.13%)
Ex-Dividend Date	Jun 22, 2026

Volume	6,385,729
Open	16.45
Previous Close	16.27
Day's Range	16.33 - 16.90
52-Week Range	13.40 - 22.94
Beta	0.43
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About Sansure Biotech

Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tract infections; nucleic acid tests and fluorescence diagnostic kits for blood-borne infections; RNA diagnostic kits for gastrointestinal infections; an... [Read more]

Industry Medical Instruments & Supplies

Sector Healthcare

Founded 2008

Employees 2,064

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688289

Full Company Profile

Financial Performance

In 2025, Sansure Biotech's revenue was 1.64 billion, an increase of 12.58% compared to the previous year's 1.46 billion. Earnings were 198.94 million, a decrease of -27.82%.

Financial Statements